Company Response to NSE Query on Financial Results
Date and Nature of Communication
Supriya Lifescience Limited submitted this clarification letter to the National Stock Exchange of India Limited on September 05, 2026. The communication was in response to an email from NSE dated September 02, 2026, which sought clarification regarding the absence of segment details in the company's quick results submission.
Company's Clarification on Segment Details
The company provided the following specific clarifications:
- The company operates in a single business segment, specifically the Pharmaceuticals segment
- At the time of the original submission on August 13, 2026, the company had selected the appropriate option under the segment column ("Single Segment")
- The selection was not displayed post-submission due to a technical error that occurred inadvertently
- The company will investigate the error to resolve it
Regulatory Compliance Reference
The company explicitly references its commitment to compliance with SEBI (LODR) Regulations, 2015. The letter states: "We reaffirm our commitment to full compliance with the SEBI (LODR) Regulations, 2015." The company also emphasizes its track record of timely and accurate disclosures and its dedication to upholding these practices in all future filings.
Additional Details
The letter was digitally signed by Prachi Suhas Sathe, Company Secretary & Compliance Officer, on September 05, 2026 at 13:01:10 IST. The communication references the Board Meeting dated August 13, 2026, and expresses sincere regret for the inadvertent error.